Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Diphteria, tetanus, and Acellular Pertussis vaccine · 2 trials · 5 indications
Immunogenicity profile of ADACEL™ (TdcP vaccine) antibody (anti-diphtheria, anti-tetanus, and anti-pertussis) responses at Day 0 and Day 28 Post-vaccination.
GMTs and 95% confidence intervals of anti-diphtheria, anti-tetanus, and anti-pertussis toxoids responses at Day 0 and Day 28 Post-vaccination.
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Diphteria/Tetanus/Polio/Acellular Pertussis/Hib vaccine | BIOLOGICAL | 0.5 mL, IM |
| Diphteria, tetanus, and Acellular Pertussis vaccine | BIOLOGICAL | 0.5 mL, Intramuscular |
Inclusion Criteria: * Aged 42 to 56 days inclusive on the day of inclusion * Born at full term pregnancy (\> 37 weeks) with a birth weight ≥ 2.5 kg * Informed consent form signed by the parent(s) or other legal representative * Able to attend all scheduled visits and to comply with all trial proced...
The Diphtheria, tetanus, and Acellular Pertussis vaccine is used to protect against diphtheria, tetanus, and pertussis (whooping cough). It is also studied for related indications including polio and Haemophilus infections. It is an infectious disease vaccine developed by Sanofi.
Sanofi develops the Diphtheria, tetanus, and Acellular Pertussis vaccine. Sanofi trades under the ticker SNY. The vaccine has been studied in Phase 3 clinical trials conducted in India and Taiwan.
The Diphtheria, tetanus, and Acellular Pertussis vaccine is in Phase 3 development. Two Phase 3 trials have been completed, with no active trials currently listed. The completed studies enrolled a total of 341 participants.
Two completed Phase 3 trials have studied the Diphtheria, tetanus, and Acellular Pertussis vaccine. NCT00259337 evaluated immunogenicity and safety in an Indian population with 226 participants. NCT00258908 evaluated immunogenicity and safety as a fifth dose in Taiwan with 115 participants.